Growing at an annualized rate of over 20%, the cell therapy manufacturing market is estimated to reach close to USD 10 Billion by 2030, claims Roots Analysis (1) - PowerPoint PPT Presentation

About This Presentation

Growing at an annualized rate of over 20%, the cell therapy manufacturing market is estimated to reach close to USD 10 Billion by 2030, claims Roots Analysis (1)


The growing global urgency to reduce carbon footprint, coupled to the long life and low maintenance requirements of lithium ion batteries, have enabled this relatively new class of portable power sources to effectively penetrate the automotive market Roots Analysis has announced the addition of “Automotive Lithium-Ion Battery Market, 2019-2030” report to its list of offerings. Owing to their numerous benefits, the sales of lithium ion battery powered cars have grown by more than 10 times over the period 2013-2019. In addition, the anticipated ban on IC engine vehicles by 2030 is likely to further drive the demand for these batteries within the automobile industry. – PowerPoint PPT presentation

Number of Views:38
Slides: 8
Provided by: RootsAnalysis


Transcript and Presenter's Notes

Title: Growing at an annualized rate of over 20%, the cell therapy manufacturing market is estimated to reach close to USD 10 Billion by 2030, claims Roots Analysis (1)

The cell and advanced therapies supply chain
management market is anticipated to grow at an
annualized rate of 11 till 2030, claims Roots
78.html https//
  • Over time, biopharmaceutical companies have
    realized the importance of integrating advanced
    software into the cell and advanced therapies
    supply chain. Such upgrades have demonstrated the
    ability to offer both time and cost saving
  • Roots Analysis has announced the addition of the
    Cell and Advanced Therapies Supply Chain
    Management Market Focus on Technological
    Solutions (Cell Orchestration Platforms,
    Enterprise Manufacturing Systems, Inventory
    Management Systems, Laboratory Information
    Management Systems, Logistics Management Systems,
    Patient Management Systems, Quality Management
    Systems, Tracking Tracing Systems, and Other
    Software), 2019-2030 report to its list of
  • The cell and advanced therapies supply chain is
    complex, with several legacy challenges, such as
    those related to patient scheduling, resource
    planning, inventory management, and deliverable
    tracking. A number of innovative,
    software-enabled systems are available / under
    development to mitigate the aforementioned
    concerns and simplify the management of
    biopharmaceutical supply chains.

  • Over 160 software-enabled supply chain management
    systems are currently available
  • Of these, more than 25 are inventory management
    systems (IMS), which are primarily used for
    tracking inventory, orders, sales and deliveries.
    Examples include (in alphabetical order) ATiM
    Software, Benchling Inventory, CryoTrackIMS,
    Cryotrax, CTM-STAR, Lynx Mobile, Mosaic
    FreezerManagement, and Stafa Apheresis.
  • 80 of marketed solutions are used in collection
    centers and sample storage warehouses
  • Further, about 49 of such systems are being
    implemented to streamline manufacturing
    operations of cell and advanced therapies
  • Cloud-based deployment is gradually gaining
  • Stakeholders claim that such deployment methods
    can be rapidly provisioned with minimal
    management effort (often over the internet),
    allowing for faster implementation. At present,
    about 47 of the software systems are being
    deployed via cloud examples include (in
    alphabetical order) Chronicle automation
    software, Cryoportal,, PAS-X MES,
    STARLIMS, tempmate-CLOUD, and TrakCel.
  • Around 57 of the stakeholders in this industry
    are based in the US
  • This can be attributed to the increasing interest
    in cell and advanced therapies in this region,
    making North America the current hub of
    innovation in this field. It is followed by
    players in the EU (35) and Asia Pacific (8).
  • 2,600 tweets focused on the increasing interest
    and ongoing efforts of industry stakeholders
  • Social media analysis revealed that many
    biopharmaceutical developers are adopting
    software-enabled supply chain management
    solutions with increasing enthusiasm. In fact,
    many of the tweets were related to the ability of
    such systems to resolve the challenges associated
    with large volumes of supply chain data.
  • Over 10 supply chain orchestration solutions are
    currently available in the market
  • These solutions have demonstrated the ability to
    efficiently integrate core software systems, in
    order to offer needle-to-needle traceability
    within complex supply chains.

  • USD 650 million has been invested by both
    private and public investors, since 2014
  • Of this, close to USD 300 million was raised
    through venture capital funding rounds,
    representing 47 of the total capital raised.
    Further, there were five instances of IPOs /
    secondary offerings, accounting for USD 280
    million in raised capital.
  • Partnership activity has increased at an
    annualized rate of 14
  • In fact, around 55 of the reported deals were
    established post 2016 the maximum partnership
    activity was observed in 2018. Majority of these
    agreements (75) were observed to be focused on
    platform integration or the establishment of
    service alliances.
  • North America and Europe are anticipated to
    capture over 85 market share by 2030
  • In addition to North America and Europe, the
    market in China / broader Asia Pacific region is
    also anticipated to grow at a relatively faster
  • To request a sample copy / brochure of this
    report, please visit this link

  • Key Questions Answered
  • What are the trending software solutions for the
    management of cell and advanced therapies supply
  • Who are the leading industry and non-industry
    players in this domain?
  • What are the key challenges faced by various
    stakeholders in this domain?
  • What kind of partnership models are commonly
    adopted by stakeholders in this industry?
  • Who are the key investors in this field?
  • What is the current and likely future cost saving
    opportunities associated with supply chain
    management solutions?
  • How is the current and future market opportunity
    likely to be distributed across key market
    segments and geographies?
  • What factors are likely to influence the
    evolution of this upcoming market?

  • The financial opportunity within the cell and
    advanced therapies supply chain management market
    has been analyzed across the following segments
  • Application area
  • Donor eligibility assessment
  • Sample collection
  • Manufacturing
  • Logistics
  • Patient verification and treatment follow-up
  • Type of software solution
  • Cell orchestration platform
  • Enterprise manufacturing system
  • Inventory management system
  • Laboratory information management system
  • Logistics management system
  • Patient management system
  • Quality management system
  • Tracking and tracing system
  • Mode of Deployment
  • Cloud-based solution
  • On-premises solution

  • Gaurav Chaudhary
  • 1 (415) 800 3415
  • 44 (122) 391 1091
  • https//
  • https//

Roots Analysis - Leaders in Pharmaceutical
Biotechnology Market Research
Write a Comment
User Comments (0)